CalciMedica Q1 2025 net loss $5.9M; cash $24.6M; KOURAGE trial data due end of 2025

CalciMedica, Inc.

2025-Q1 EPS reported -$0.36

Net loss of $5.9M in Q1 2025 vs. net income of $0.1M in Q1 2024; R&D expenses rose to $4.2M.
Cash, cash equivalents and short-term investments of $24.6M; runway expected into mid-2026.
Phase 2 KOURAGE trial (AKI + respiratory failure) enrollment ongoing; data expected around end of 2025.
Post-hoc analysis from CARDEA showed 62.7% relative mortality reduction for Auxora vs. placebo in AKI subset.
End-of-Phase 2 meeting with FDA for AP/SIRS planned mid-2025; credit facility with Avenue Capital ($32.5M total).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.